TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07618195: Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia

Sponsor: Epibiotech · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 42 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,017,600

Rescue Site Savings

+$4,627,230

Unlock Full NCT07618195 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07618195 Rescue Dossier →